Description: MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. The company was incorporated in 2018 and is headquartered in Kelowna, Canada.
Home Page: www.myndsciences.com
733 Finns Road
Kelowna,
BC
V1X 5B7
Canada
Phone:
403 559 6779
Officers
| Name | Title |
|---|---|
| Dr. Wilfred A. Jefferies | Co-Founder, Chairman & Chief Science Officer |
| Dr. Lyle Oberg M.D. | Co-Founder, CEO & Director |
| Mr. Lih-Ming Tam | Interim CFO & Sr. Controller |
| Dr. Chaahat S.B Singh | Sr. Operations & Research Mang. |
| Mr. Luke Warkentin | VP of Corp. Devel. |
| Dr. Iryna Saranchova Ph.D. | Chief Clinical Officer |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | October |
| Full Time Employees: | 0 |